A Safety Study of Dapivirine (TMC120) Vaginal Microbicide Gel in South Africa

Summary

Approximately 42 HIV-negative women, aged \>18 and \< 50, will be enrolled in this study. Each volunteer will have a 2:1 chance of receiving Dapivirine Gel-002 versus placebo. The volunteers will receive investigational product for a total of 42 days.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications